De-escalating chemoradiotherapy may be a feasible strategy for some patients with stage IIA or IIB classic seminoma, suggest the SAKK 01/10 trial investigators.

Hypofractionated image-guided radiotherapy does not improve survival relative to conventional radiotherapy in patients with stage II or III non-small-cell lung cancer ineligible for concurrent chemoradiotherapy, research shows.

For patients with unresectable stage III non-small-cell lung cancer, first-line pembrolizumab plus concurrent chemoradiotherapy is feasible, say the KEYNOTE-799 investigators.

Adding pembrolizumab to concurrent first-line chemoradiotherapy is tolerable and shows promising efficacy in patients with locally advanced non-small-cell lung cancer, according to phase 1 study data published in JAMA Oncology.

Preliminary findings from the PREOPANC -1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46) Watch the accompanying expert commentary .

The overall survival of patients with resectable gastric cancer who have received adequate preoperative chemotherapy and surgery does not differ according to whether or not they receive postoperative chemoradiotherapy, phase III trial data show.

Cisplatin chemoradiotherapy significantly delays disease recurrence and improves survival compared with radiotherapy alone in women with stage IIIB squamous cell carcinoma of the cervix, phase III study data show.

Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy results in a high margin-negative resection rate in patients with borderline resectable pancreatic cancer, phase II trial data show.

Pelvic control was good for women receiving chemoradiotherapy or radiotherapy.

The team explains that bladder-preserving trimodality therapy with transurethral bladder tumor resection and cisplatin-based chemoradiotherapy “can be an effective alternative to radical cystectomy” for MIBC, “but biomarkers are needed to guide optimal patient selection.”

Incidental irradiation of the sinoatrial node during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation and death, research suggests.

A US National Cancer Database analysis suggests that immunotherapy after chemoradiotherapy for unresectable stage III non-small-cell lung cancer is associated with an overall survival benefit in the general US population.

Final analysis of progression-free survival in the GEMSTONE-301 trial shows a significant improvement with use of sugemalimab versus placebo after chemoradiotherapy for stage III unresectable non-small-cell lung cancer, report Chinese researchers at the IASLC World Conference on Lung Cancer 2022 in Vienna, Austria.

Individuals with limited-stage small-cell lung cancer could benefit from the addition of durvalumab to chemoradiotherapy, suggest early data.

The patient-specific assays the authors describe were created by first sequencing tumor samples from 88 patients with early-stage NSCLC (62.5% adenocarcinomas) who were treated by surgery (n=61), surgery with adjuvant chemotherapy or radiotherapy (n=8), or chemoradiotherapy alone (n=19).

The team concludes: “Overall, efficacy and safety data from GEMSTONE-301 support the potential use of sugemalimab as an effective consolidation therapy for patients with unresectable stage III NSCLC, whose disease has not progressed after sequential or concurrent chemoradiotherapy.

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.